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Introduction
Breast cancer development and progression are strongly influ-
enced by estradiol, which acts by inducing cell proliferation and
inhibiting apoptosis. Agents able to modify estradiol action in
target cells as well as their circulating levels and metabolic path-
ways are of great interest for therapeutic intervention. Among
them, sex hormone-binding globulin (SHBG) has received in-
creasing attention over time due to its unique ability to bind cir-
culating estradiol at high affinity [1] and regulate estradiol ac-
tion within the cell [2].
Levels of circulating SHBG have been widely studied in breast
cancer patients together with other potential risk factors. In
postmenopausal breast cancer patients, SHBG plasma levels are
reduced or at least at the lower end of normal range [3 –5]; in
these patients, the free fraction of estradiol is, on the other
hand, increased in relation to an absolute or relative reduction
of SHBG [6]. Moreover, a recent reanalysis of nine prospective
studies on breast cancer risk concluded that SHBG in postmeno-
pausal women is associated with a decrease in breast cancer risk
[7].
It should also be remembered that in the late 70s some authors
reported that SHBG plasma levels were increased in estrogen re-
ceptor-positive breast cancer patients [8– 10].
In addition, some authors reported the presence of immunoreac-
tive SHBG in breast cancer cells and tissue sections [11 – 15], as
well as the demonstration of SHBG mRNA [16]. Unfortunately,
studies showing the presence of SHBG mRNA failed to provide
conclusive evidence for the presence of the protein, and conclu-
sions based on experiments using human tissue section are am-
biguous overall. Lastly, no convincing functional role for this hy-
pothetical intracellular protein in breast cancer has ever been de-
lineate.
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Abstract
Sex Hormone-binding Globulin (SHBG) is a plasma glycoprotein
that regulates the action of steroid hormones at several levels.
SHBG regulates the availability of free androgens and estradiol
to hormone-responsive tissues. Moreover, SHBG is also part of a
novel steroid signaling system. We report here on the mecha-
nism of action and the biological effects of SHBG in breast cancer
cells, especially distinguishing cross-talk between membrane-
initiated SHBG and estradiol pathways. After interacting with a
specific binding site on breast cancer cell membranes, SHBG ac-
tivates a specific pathway, and by cAMP induction, inhibits es-
tradiol-mediated activation of ERK. Both estradiol and SHBG
membrane-initiated pathways involve cross-talk at MAP kinase
level with the ultimate result of inhibiting estradiol-mediated
cell growth and antiapoptosis. On the basis of reported evidence,
we suggest that SHBG is one of the regulators of growth and
apoptosis of estrogen-dependent breast cancer cells.
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Taking all these data into account, it is clear that some functional
relationship between SHBG and breast cancer must exist. Provid-
ed that the regulation of the bioavailable free estradiol fraction
has a meaningful role, at least in postmenopausal women, the di-
rect effect of SHBG on estradiol action in breast cancer cells and
the pathways triggered will be the subject of the present discus-
sion.
SHBG Binds to Breast Cancer Cell Membrane
The suggestion that SHBG could play an active role at the level of
the cell membrane is driven by reports regarding the presence of
specific and high-affinity binding sites for SHBG on cell mem-
branes from endometrium [17– 19], prostate [20], human pla-
centa [21], and epididymis [22]. More recently, binding sites for
SHBG have also been described in medial preoptic area and med-
ial basal hypothalamus in rats [23], while SHBG-receptor interac-
tion has been suggested as responsible for many steroid effects in
brain and peripheral cells [24,25]. Furthermore, specific binding
sites for SHBG were also described on membranes of estrogen-
dependent MCF-7 breast cancer cells [26,27].
The binding characteristics of SHBG to cell membranes are con-
sistent with the presence of a receptor structure. In fact, all the
authors described binding that is highly specific and dependent
on time and temperature in the different tissues. Unfortunately,
no data are available on receptor structure, and its gene has not
been identified and characterized yet. Nonetheless, our knowl-
edge about the binding modalities of SHBG to membranes is
quite exhaustive. As elegantly described by Hryb and coworkers
[28, 29], we are aware that only steroid-free SHBG binds to cell
membranes; on the other hand, where sex steroids bind to
SHBG first, they prevent SHBG-cell interaction; the magnitude
of the inhibition is directly proportional to the magnitude of the
association constant for the steroid-SHBG interaction. Once
bound to the membrane site, SHBG binds steroids with equal af-
finity to that in solution. Lastly, this mechanism of successive
binding is crucial in triggering the biological effects of SHBG in
target cells as will be discussed below.
The SHBG domain that interacts with cell membranes has also
been identified, at least in part [30]. It is localized to a ten-ami-
no-acid stretch (TWDPEGVIFY) in the amino-terminal end of the
SHBG molecule. This region, also referred to as laminin-G do-
main of human SHBG [30, 31], is the most highly conserved por-
tion of the molecule across species [30] and in related proteins
such as protein S, laminin A, merosin, and Drosophila crumbs pro-
tein [30, 32,33].
Moreover, the biological effect of SHBG on MCF-7 breast cancer
cell proliferation (which will be described in detail in the next
paragraphs) depends on the structural integrity of the O-glycosy-
lation site in Thr7 [34]. While SHBG mutants lacking the two N-
glycosylation sites located in the carboxy-terminus of the protein
show activity no different from breast cancer cell proliferation
seen in wild type protein, the mutant SHBG lacking Thr7 O-glyco-
sylation in its amino terminus fails to block cell growth.
Taking all these observations together, SHBG clearly interacts
with cell membranes at its amino-terminus portion, the lami-
nin-G domain. The carbohydrate chain in this domain contri-
butes to its structural stability, and allows correct binding to
cell membranes and induction of SHBG’s biological effects in
breast cancer cells.
SHBG and Estradiol Pathways Cross-talk after Membrane
Initiation
As mentioned above, SHBG recognizes a specific binding site lo-
cated on cell membranes of estrogen-dependent MCF-7 breast
cancer cells [26,27]. On the other hand, no binding was detect-
able on MDA-MB 231 breast cancer cells negative for estrogen re-
ceptor alpha (ERa) and generally considered estrogen-insensi-
tive [35]. Furthermore, when SHBG binding was evaluated on tis-
sue samples from breast cancer patients, it was detectable on
75 % of ERa-positive samples but only in 37 % of ERa-negative
samples. In addition, samples binding SHBG and expressing ERa
were also characterized by a significantly lower proliferation rate
than samples not able to bind SHBG. So far, it appears that SHBG
action in breast cancer cells must be strictly linked to estradiol
effects in these cells [36].
A membrane-initiated effect of estradiol has been hypothesized
for a long time, but was not described in detail until recently. In
fact, beside the classical pathway mediated by the nuclear ER, es-
tradiol binds to a putative membrane ER [37] and triggers specif-
ic intracellular signal transduction pathways [38]. There is mem-
brane-initiated pathway cross-talks at several points with path-
ways initiated by growth factors such as EGF [39]. Both pathways
– one induced by growth factors and mediated by membrane ER
– induce activation of MAP kinase that transmits and amplifies
signals involved in both cell proliferation and apoptosis [40 –
42]. Moreover, MAP kinase can directly catalyze the phosphory-
lation of serine 118 of nuclear ERa, thus increasing ER transcrip-
tional efficiency [43]. The result of this multiple-site cross-talk is
strong signal amplification and, finally, potent stimulation of cell
growth and inhibition of apoptosis.
After binding to MCF-7 cell membranes, SHBG triggers down-
stream signaling, which starts with an increase in intracellular
cAMP. The accumulation of cAMP induced by SHBG has been de-
scribed both in prostate [44, 45] and breast [35,46] cancer cells;
the main difference between the two cell types was reported to
lie in the steroid that activated SHBG after membrane binding;
DHT in the prostate and estradiol in breast cancer cells. SHBG in-
duced an elevation in intracellular cAMP, suggesting that the pu-
tative SHBG receptor is coupled to a G-protein [47], but evidence
for it is still lacking. However, the biological effects of SHBG ap-
peared to be mediated by cAMP and its target PKA. In fact, biolo-
gical effects of SHBG [48, 49] are lost in MCF-7 cells when PKA is
blocked by the specific inhibitor, PKI (6 – 22).
The immediate target of increased PKA in breast cancer cells
after SHBG activation has not yet been identified, but new data
suggest that increased PKA levels can inhibit the MAP kinase
pathway. In fact, we demonstrated that SHBG, after membrane
binding, counteracts the estradiol-induced ERK activation [50],





































which is one of the MAP kinases involved in cell proliferation
control. ERK activity is suppressed by both cAMP and PKA as re-
ported by Filardo and co-workers [51]. Lastly, inhibition of ERK
may result in both removal of anti-apoptotic effects caused by
estradiol as we have demonstrated [50], and reduction of ERa
transcription efficiency [43]. The evoked pathways and the pos-
tulated cross-talk between estradiol and SHBG in breast cancer
cells are reported in Fig.1.
SHBG Modulates Estradiol-regulated Effects in Breast Cancer
Cells
Membrane-initiated SHBG and estradiol pathways are therefore
likely to be subject to cross-talk in breast cancer cells. As men-
tioned above, SHBG is able to counteract estradiol induction of
MAP kinase, thus reducing estradiol efficacy. The SHBG-estradiol
cross-talk is therefore likely to interfere with biological estradiol
effects in breast cancer cells.
One of the markers of estradiol efficacy in breast cancer is the in-
duction of the progesterone receptor (PR) expression. In MCF-7
cells treated with estradiol, the steroid greatly upregulates PR
levels measured either by gene expression or by functioning pro-
tein [52, 53]. When MCF-7 cells are treated with SHBG first and
then with estradiol, both RNA and protein PR levels do not
change with respect to basal levels; the induction of PR by estra-
diol is thus inhibited by SHBG [48]. Moreover, the effect of SHBG
on estradiol regulation of PR is highly specific for the protein
since it is abolished by anti-SHBG antibody and depends on the
affinity of estradiol for SHBG (DES, estrogenic compound binding
to the estrogen receptor but not to SHBG, is able to up-regulate
PR even in the presence of SHBG).
Beside apart from the anti-estrogenic effect on PR, SHBG has
been widely demonstrated to inhibit estrogen-dependent cell
growth. Estradiol is well known to induce and maintain the pro-
liferation of breast cancer cells [54], and the effect of estradiol on
breast cancer cell growth is due to the activation of multiple
pathways. First the hormone, through its nuclear receptor ERa,
regulates the transcription and expression of many genes in-
volved in cell proliferation, inducing positive regulators of cell
growth while inhibiting negative regulators [55, 56]. Second, es-
tradiol by interacting with its membrane receptor (ERm) [37] ac-
tivates ERK and inhibits Jun kinase, causing the induction of bcl-
2 and thus the inhibition of apoptosis in MCF-7 breast cancer
cells [38]. Since one of the first descriptions of the SHBG binding
site on MCF-7 cells [27], interaction between SHBG with its re-
ceptor in breast cancer cells was demonstrated to inhibit estra-
diol-induced cell proliferation. Some years later, we confirmed
our previous observation and described in detail this effect of
SHBG in MCF-7 cells [49]. The antiproliferative effect of SHBG is
detectable when the correct sequence of binding is followed;
that is, first, SHBG binds to its membrane-associated receptor
on MCF-7 cells, then estradiol binds at the steroid-binding site
of SHBG. Recombinant SHBG produced by MCF-7 cells transfect-
ed with human shbg gene was shown to retain all the anti-pro-
liferative properties of the SHBG [34] while, much more interest-
ingly, MCF-7 cells producing SHBG after transfection completely
lose their capacity to bind SHBG at membranes.
Furthermore, SHBG was recently reported to inhibit another es-
tradiol effect that has great importance in the control of cell pro-
liferation. As mentioned above, estradiol inhibits apoptosis in
MCF-7 cells and does it by interacting with its membrane recep-
tor, ERm [38]. SHBG [50] is capable of reversing the anti-apopto-
tic effect of estradiol; in MCF-7 cells, it does so when used in
physiological concentrations and, again, only when the correct
sequence of binding is followed. Moreover, the structural integri-
ty of the O-glycosylation site in Thr7 of the amino-terminal end of
SHBG is required to block the estradiol antiapoptotic effect [50]
as already reported for the inhibition of cell proliferation induc-
tion [31]. In addition, SHBG blocks the estradiol anti-apoptotic
effect without affecting estradiol-regulated transcription, as
demonstrated in a general transcriptional assay using an ERE-
tk-luciferase system [50].
As seen in Fig.1, we postulate the existence of cross-talk between
the SHBG membrane-initiated pathway and estradiol mem-
brane-elicited effects in breast cancer cells. First, SHBG binds to
its membrane associated receptor (SHBG-R), and then the glyco-
protein itself binds to estradiol activating a second messenger
pathway that demonstrates increased cAMP and PKA accumula-
tion. Estradiol alone, on the other hand, after interacting with its
own membrane-associated receptor (ERm), stimulates another
pathway resulting in ERK phosphorylation, which is finally in-
volved in apoptosis inhibition and cell proliferation induction.
As indicated, the former SHBG-stimulated pathway inhibits this
ERm-stimulated pathway; the result is that SHBG stimulation in-
hibits ERK phosphorylation. Therefore, there is an antagonistic
relationship between the SHBG and estradiol stimulated effects
in breast cancer cells.
Finally, the inhibition of estradiol effects in breast cancer cells by
SHBG requires structural characteristics and biochemical events
supporting at least two assumptions: first, SHBG might interact
Fig. 1 SHBG and estradiol pathways in breast cancer cells. In its ste-
roid-free configuration, SHBG binds to its receptor (SHBG-R). After
binding to estradiol (E2), the complex activates adenylyl cyclase, lead-
ing to cAMP generation, which in turn inhibits ERK. Estradiol can also
bind either to its membrane receptor (ERm), leading to ERK activation,
or to the intracellular ER (ERa), activating the genomic pathway. There-
fore, SHBG and estradiol membrane-initiated pathways have opposite
effect on cell growth and apoptosis.





































with cell membranes at a specific site and, second, the SHBG ef-
fect is not due to a simple sequestration of circulating estradiol,
but requires the activation of specific pathways.
Conclusions
SHBG is now believed to be a multifunctional protein, and its role
in estrogen signaling is of biological relevance. In estrogen-de-
pendent breast cancer, in particular, SHBG functions as a nega-
tive modulator of estradiol action and should no longer be con-
sidered as a passive player, as its action in breast cancer cells re-
quires an active role. The inhibition of estradiol effects by SHBG
requires the interaction of SHBG with cell membranes at a specif-
ic site and the activation of specific pathways since this is not due
to a simple sequestration of circulating estradiol. Furthermore,
both estradiol and SHBG membrane-initiated pathways are sub-
ject to cross-talk at MAP kinase level with the ultimate result of
inhibiting estradiol-mediated cell growth and antiapoptosis.
The recent evidence supporting the cross-talk between estradiol
and SHBG pathways has far-reaching implications for the intra-
cellular signaling network involved in breast cancer initiation
and progression. In conclusion, it appears from the growing
body of evidence that SHBG is one of the regulators of growth
and apoptosis of estrogen-dependent breast cancer cells, with a
final antiproliferative effect.
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